Endocrine therapy was excluded in this trial, yet is frequently added after the completion of taxane therapy in routine practice, as endorsed in the guidelines [7] and supported by the registHER and SystHER observational studies, which showed clinically meaningful improvements in outcomes of patients with HR+/HER2+ BC treated with maintenance endocrine therapy [75,76]. This evidence concerns the gene HR and breast cancer.